SCOTUS Takes Up Mifepristone Rx Conditions But Won’t Revisit FDA’s Approval

The Supreme Court announced Wednesday (Dec. 13) it will consider whether to invalidate FDA’s relaxed prescribing conditions for the abortion pill mifepristone but will not contemplate overturning the agency’s original 2000 approval of the drug -- a move that averts consideration by the high court justices of whether to second-guess an FDA approval decision, which the drug industry had warned would have far-reaching implications for the scope of the agency’s authority.